# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Reuters
- Bloomberg
- Reuters
DESTINY-Breast06 results show Daiichi Sankyo and AstraZeneca's ENHERTU is the first HER2 directed medicine and antibody d...
Positive results from the LAURA Phase III trial showed AstraZeneca's Tagrisso (osimertinib) demonstrated a statistically si...
Results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI®(durvalumab) demonstrated statistically significant and...
- Dow Jones Citing Interview